No profile data available.
Vaxcyte, Inc. (PCVX) is a healthcare company in the antibacterial pharmaceuticals industry, based in San Carlos, United States, with about 507 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$766.63 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $10.62 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Vaxcyte reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$10.62 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include Insmed Incorporated (INSM), AN2 Therapeutics, Inc. (ANTX), BGM Group Ltd. (BGM), Armata Pharmaceuticals, Inc. (ARMP).